HOME > ORGANIZATION
ORGANIZATION
- Over 20% of All Generics under Restricted Shipments: FPMAJ
March 14, 2023
- PhRMA Unveils Proposal for FY2024 Reform, Says This Year Is “Turning Point” to Improve Access
March 10, 2023
- Labor Unions Prod MHLW to Renew Efforts to Improve Compliance with Drug Distribution Guidelines
March 3, 2023
- OB/GYN Group Urges MHLW to Facilitate Access to Oral Abortion Drug
February 24, 2023
- Policy Veterans’ Group Floats Proposal to Prevent Unprofitability to Stabilize Drug Supply
February 21, 2023
- JPMA Chief Calls for Prompt Price Cuts for LLPs, Generic Industry Consolidation
February 17, 2023
- Japan Citizen’s Group Objects Pfizer’s Partnership with Tokyo Govt
February 1, 2023
- PhRMA Poised to Issue 2024 Reform Proposal in Next Few Months: New Japan Chief
January 25, 2023
- Kenporen Director Calls on Pharma Industry, MHLW to Share More Data toward FY2024 Reform
January 20, 2023
- JPMA Now Finalizing Policy Proposal 2023, Due Out “before Cherry Blossoms”
January 20, 2023
- Japan Pharma Lobbies Look Set to Shift to Okada/Ueno Leadership towards FY2024 Reform
January 17, 2023
- ALS Patient Group Petitions for Early Approval of Relyvrio in Japan
January 12, 2023
- FPMAJ Chief Poised to Push Rethink of Price Revision Rules towards FY2024 Reform
January 11, 2023
- Japan Pharma Leaders Want to Thwart “Drug Loss,” Return of Lag: New Year’s Messages
January 5, 2023
- FPMAJ Calls on Drug Makers to Lift Shipment Controls of 233 APIs/Specifications
December 28, 2022
- Generic Use Rate Hits Record 80.3% in July-September: JGA
December 28, 2022
- Hodanren Questions Special PMP Measure in Off-Year Drug Price Revision
December 27, 2022
- Product Coverage for FY2023 Price Revision “Deeply Regrettable”: FPMAJ
December 22, 2022
- Japan Hospital Federation Calls for Drug Pricing Overhaul in FY2024
December 20, 2022
- Japan Citizen’s Group Opposes NIP Inclusion of Silgard 9
December 19, 2022
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…